| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg | |||
| Other Sizes |
| Targets |
(R)-Mirtazapine D3 targets the same receptors as its unlabeled parent drug. Mirtazapine is an atypical antidepressant and a 5-HT2/3 receptor inhibitor. (R)-Mirtazapine is a 5-HT3 receptor antagonist. By blocking these receptors, it modulates neurotransmitter release in the central nervous system.
|
|---|---|
| ln Vitro |
In vitro, (R)-Mirtazapine D3 is characterized as a deuterated form of (R)-Mirtazapine. Mirtazapine is an atypical antidepressant that acts as a 5-HT2/3 receptor inhibitor. (R)-Mirtazapine has antinociceptive properties in an animal model of acute thermal nociception. The deuterated form is used primarily as an analytical standard.
|
| ln Vivo |
In vivo, Mirtazapine is used as an atypical antidepressant for the treatment of major depressive disorder. (R)-Mirtazapine has antinociceptive properties. (R)-Mirtazapine D3 serves as a critical tool in pharmacokinetic studies to accurately track drug absorption, distribution, metabolism, and excretion. It is used as an internal standard for bioanalysis.
|
| Enzyme Assay |
In vitro receptor binding assays for (R)-Mirtazapine D3 are typically performed as part of analytical method validation. The compound is used as an internal standard in LC-MS/MS assays for the quantification of Mirtazapine. It is dissolved in an appropriate solvent and spiked into biological matrices at known concentrations. Calibration curves are generated by plotting the peak area ratio of Mirtazapine to (R)-Mirtazapine D3 against the concentration of Mirtazapine.
|
| Cell Assay |
For in vitro cell-based assays, (R)-Mirtazapine D3 can be used in studies investigating Mirtazapine's cellular effects, though its primary use is as an analytical internal standard. Cells expressing 5-HT receptors are cultured and treated with the compound. Receptor antagonism is confirmed by measuring downstream signaling pathways. However, due to its role as an internal standard, it is more frequently used in analytical quantification.
|
| Animal Protocol |
In vivo animal studies with (R)-Mirtazapine D3 are primarily pharmacokinetic. The compound is administered orally to rodents, and blood samples are collected at predetermined time points. Plasma concentrations of both labeled and unlabeled Mirtazapine are analyzed by LC-MS/MS using (R)-Mirtazapine D3 as the internal standard. Pharmacodynamic effects can be evaluated in behavioral models of depression.
|
| ADME/Pharmacokinetics |
(R)-Mirtazapine D3 (CAS: 61364-37-2) has a molecular weight of 268.37 g/mol and a molecular formula of C₁₇H₁₆D₃N₃. Appearance: White to off-white solid powder. LogP: 2.75. Storage: Powder -20°C 3 years, 4°C 2 years; In solvent -80°C 6 months, -20°C 1 month.
|
| Toxicity/Toxicokinetics |
As a deuterium-labeled analog of an approved antidepressant, (R)-Mirtazapine D3 is expected to have a similar toxicity profile to Mirtazapine, though toxicity studies are typically not performed on the labeled compound. Mirtazapine is generally well-tolerated, with common side effects including sedation and weight gain. The compound is used in very small quantities as an analytical internal standard.
|
| References |
|
| Additional Infomation |
LSM-5894 is an organic heterobicyclic compound and an organic nitrogen heterocyclic compound.
See also: Mirtazapine (note moved to). (R)-Mirtazapine D3 is a tri-deuterated form of (R)-Mirtazapine, the R-enantiomer of Mirtazapine. Mirtazapine is an atypical antidepressant and a 5-HT2/3 receptor inhibitor. (R)-Mirtazapine has antinociceptive properties. The labeled compound is used as an internal standard for analytical and pharmacokinetic studies. It is not intended for therapeutic use. |
| Molecular Formula |
C₁₇H₁₆D₃N₃
|
|---|---|
| Molecular Weight |
268.37
|
| Exact Mass |
265.157
|
| CAS # |
61364-37-2
|
| Related CAS # |
Mirtazapine;85650-52-8;(S)-Mirtazapine;61337-87-9;(S)-Mirtazapine-d3;Mirtazapine-d3;1216678-68-0;(R)-Mirtazapine-d3
|
| PubChem CID |
3085219
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
432.4±45.0 °C at 760 mmHg
|
| Flash Point |
215.3±28.7 °C
|
| Vapour Pressure |
0.0±1.0 mmHg at 25°C
|
| Index of Refraction |
1.668
|
| LogP |
2.75
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
20
|
| Complexity |
345
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
N12C3C(=CC=CN=3)CC3C=CC=CC=3[C@@H]1CN(C)CC2
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.7262 mL | 18.6310 mL | 37.2620 mL | |
| 5 mM | 0.7452 mL | 3.7262 mL | 7.4524 mL | |
| 10 mM | 0.3726 mL | 1.8631 mL | 3.7262 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
